ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (TDF / FTC) in women with HIV.

The open-label, international, multi-centre study enrolled 495 treatment-naïve adult women.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The data showed statistically superior viral suppression (HIV-1 RNA <50 c/mL) rates at week 48% to 82% versus 71%  respectively.

Non-inferiority, as well as superiority endpoints were met, with superiority being driven by lower rates of both virological failures and discontinuations due to adverse events (AEs) in the dolutegravir / abacavir / lamivudine group.

"We are committed to ensuring that the specific treatment needs of women are investigated."

The safety profile of dolutegravir / abacavir / lamivudine was found to be favourable compared to ATV/r plus TDF/FTC, as fewer drug-related AEs reported on the dolutegravir / abacavir / lamivudine arm (33% vs 49%). There were also fewer AEs leading to discontinuation compared to those in the ATV/r and TDF/FTC arm (4% vs 7%).

Drug-related AEs reported in the dolutegravir / abacavir / lamivudine arm included, nausea, diarrhoea,  headache, and dyspepsia .

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the ATV/r and TDF/FTC group, drug-related AEs included nausea, diarrhoea, ocular icterus, dyspepsia, headache, and jaundice.

Fewer subjects met virologic non-response criteria (VL >50c/mL) in the dolutegravir / abacavir / lamivudine arm (6%) compared to the other group (14%) at week 48.

Of the women that met protocol-defined virologic withdrawal criteria, none on the dolutegravir / abacavir / lamivudine arm had treatment-emergent resistance mutations to the components of dolutegravir / abacavir / lamivudine, compared with one in the comparator group.

ViiV Healthcare chief scientific and medical officer John Pottage said: "Women account for more than half of the almost 35 million adults living with HIV worldwide, yet unfortunately they are consistently under-represented in HIV clinical trials.

"For this reason, we are committed to ensuring that the specific treatment needs of women are investigated.

“This trial not only provides physicians with important additional information about Triumeq, it also builds on the strong body of evidence supporting the efficacy of dolutegravir-based regimens in a broad range of patient populations."